AstraZeneca is a British-Swedish multinational pharmaceutical and biotechnology company. They are focused on creating genuinely innovative medicines and improving access to them. In this way, Astrazeneca deliver the greatest benefit to patients, healthcare systems and societies globally. Astrazeneca’s business is organised to deliver innovation tools through three strategic priorities: oncology, rare disease and biopharamceuticals.
Researchers implicated in the project: Sandra Wimberger, Nina Akrap and Panagiotis Antoniou